Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Structural insights into a shared mechanism of human STING activation by a potent agonist and an autoimmune disease-associated mutation.

Zuoquan Xie | Zhen Wang | Fengying Fan | Jinpei Zhou | Zhaoxue Hu | Qingxia Wang | Xiyuan Wang | Qingzhong Zeng | Yan Zhang | Jiaxuan Qiu | Xiaoqian Zhou | Hui Xu | Hudagula Bai | Zhengsheng Zhan | Jian Ding | Huibin Zhang | Wenhu Duan | Xuekui Yu | Meiyu Geng
Cell discovery | 2022

Stimulator of interferon gene (STING) is increasingly exploited for the potential in cancer immunotherapy, yet its mechanism of activation remains not fully understood. Herein, we designed a novel STING agonist, designated as HB3089 that exhibits robust and durable anti-tumor activity in tumor models across various cancer types. Cryo-EM analysis reveals that HB3089-bound human STING has structural changes similar to that of the STING mutant V147L, a constitutively activated mutant identified in patients with STING-associated vasculopathy with onset in infancy (SAVI). Both structures highlight the conformational changes of the transmembrane domain (TMD), but without the 180°-rotation of the ligand binding domain (LBD) previously shown to be required for STING activation. Further structure-based functional analysis confirmed a new STING activation mode shared by the agonist and the SAVI-related mutation, in which the connector linking the LBD and the TMD senses the activation signal and controls the conformational changes of the LBD and the TMD for STING activation. Together, our findings lead to a new working model for STING activation and open a new avenue for the rationale design of STING-targeted therapies either for cancer or autoimmune disorders.

Pubmed ID: 36513640

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: China Postdoctoral Science Foundation,
    Id: 2020M681427

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


BALB/cAnNCrl (tool)

RRID:MGI:2683685

laboratory mouse with name BALB/cAnNCrl from MGI.

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

B16-F10 (tool)

RRID:CVCL_0159

Cell line B16-F10 is a Cancer cell line with a species of origin Mus musculus (Mouse)

View all literature mentions

HEK293-F (tool)

RRID:CVCL_6642

Cell line HEK293-F is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions

CT26 (tool)

RRID:CVCL_7254

Cell line CT26 is a Cancer cell line with a species of origin Mus musculus

View all literature mentions